Extract
There is a clear need for a high-quality broth microdilution (BMD) assay for quantitative antimicrobial susceptibility testing (AST) for the Mycobacterium tuberculosis complex (MTBC) [1]. The BMD plate developed by the CRyPTIC Consortium, therefore, represents an important advance [2]. However, the analysis of the resulting data has several limitations.
Abstract
Provisional epidemiological cut-off values for M. tuberculosis complex need to be set carefully http://bit.ly/3XjJ8px
Acknowledgements
C.U. Köser is a visiting scientist at the Department of Genetics, University of Cambridge, and research associate at Wolfson College, University of Cambridge. Feedback from G. Kahlmeter, T. Schön and J. Turnidge was gratefully received. We thank L. Sonnenkalb for clarifications regarding her work.
Footnotes
Conflicts of interest: C.U. Köser is a consultant for Becton Dickinson, the Foundation for Innovative New Diagnostics, the TB Alliance, and the WHO Global TB Programme; C.U. Köser's consulting for Becton Dickinson involves a collaboration with Janssen and Thermo Fisher Scientific; C.U. Köser is collaborating with PZA Innovation and is an unpaid advisor to GenoScreen; has worked as a consultant for QuantuMDx, the Stop TB Partnership, and the WHO Regional Office for Europe; has given a paid educational talk for Oxford Immunotec; and has been an unpaid advisor to BioVersys and Cepheid. Hain Lifescience covered C.U. Köser's travel and accommodation to present at a meeting. F.P. Maurer is an employee of Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
- Received December 12, 2022.
- Accepted January 9, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org